Healing chronic wounds

BMJ

Volumn 324, Issue 7330, 2002, Pages 160-163

  Harding, K G ^a   Morris, H L ^a   Patel, G K ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECAPLERMIN; PLATELET DERIVED GROWTH FACTOR;

BIOENGINEERING; DIABETIC FOOT; HUMAN; LEG ULCER; PRIORITY JOURNAL; REVIEW; SKIN INJURY; SKIN TRANSPLANTATION; ULCER HEALING; WOUND; WOUND HEALING;

ADMINISTRATION, TOPICAL; BANDAGES; CHRONIC DISEASE; GROWTH SUBSTANCES; HUMANS; SKIN TRANSPLANTATION; SKIN, ARTIFICIAL; TISSUE ENGINEERING; TRANSPLANTATION, AUTOLOGOUS; WOUND HEALING; WOUNDS AND INJURIES;

EID: 0037132799     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.324.7330.160     Document Type: Article

References (30)

1. Harding KG. The future of wound healing.In: Leaper DJ,Harding KJ,eds. Wounds: biology and management. Oxford: Oxford University Press, 1998: 191.
2. Currie CJ, Morgan CL, Peters JR. The epidemiology and cost of inpatient care for peripheral vascular disease, infection, neuropathy and ulceration in diabetes. Diabetes Care 1998; 21: 42–48.
3. Reiber GE. Diabetic foot care: financial implications and practical guidelines. Diabetes Care 1992; 15(suppl 1): 29–31.
4. Ruckley CV. Socio-economic impact of chronic venous insufficiency and leg ulcers. Angiology 1997; 48: 67–69.
5. Waterlow J. Prevention is better than cure. Nurs Times 1988; 84: 69–70.
6. Yamada KM, Clark RAF. Provisional matrix.In: Clark RAF,ed. The molecular and cellular biology of wound repair. 2nd ed. London: Plenum Press, 1996: 51–94.
7. Cooper DM, Yu EZ, Hennessey P, Ko F, Robson MC. Determination of endogenous cytokines in chronic wounds. Ann Surg 1994; 219: 688–692.
8. Clark RAF. Biology of dermal wound repair. Dermatol Clin 1993; 11: 647–666.
9. Mauch C, Krieg T, Bauer EA. Role of the extracellular matrix in the degradation of connective tissue. Arch Dermatol Res 1994; 287: 107–114.
10. Hunt TK. Basic principles of wound healing. J Trauma 1990; 30: 122–18s.
11. Higley HR, Ksander GA, Gerhardt CO, Falanga V. Extravasation of macromolecules and possible trapping of transforming growth factor-beta in venous ulceration. Br J Dermatol 1995; 132: 79–85.
12. Bucalo B, Eaglstein WH, Falanga V. Inhibition of cell proliferation by chronic wound fluid. Wound Repair Regen 1993; 1: 181–186.
13. Barrick B, Campbell EJ, Owen CA. Leukocyte proteinases in wound healing: roles in physiologic and pathological processes. Wound Repair Regen 1999; 7: 410–422.
14. Agren MS, Steenfos HH, Dabelsteen S, Hansen JB, Dabelsteen E. Proliferation and mitogenic response to PDGF-BB of fibroblasts isolated from chronic venous leg ulcers is ulcer-age dependant. J Invest Dermatol 1999; 112: 463–469.
15. Hasan A, Murata H, Falabella A, Ochoa S, Zhou L, Badiavas E, et al. Dermal fibroblasts from venous ulcers are unresponsive to the action of transforming growth factor-beta 1. J Dermatol Sci 1997; 16: 59–66.
16. Stanley AC, Park HY, Phillips TJ, Russakovsky V, Menzoian JO. Reduced growth of dermal fibroblasts from chronic venous ulcers can be eliminated with growth factors. J Vasc Surg 1997; 26: 994–999.
17. Colin D, Loyant R, Abraham P, Saumet JL. Changes in sacral transcutaneous oxygen tension in evaluation of different mattresses in the prevention of pressure ulcers. Adv Wound Care 1996; 9: 25–28.
18. Boulton AJ, Bowker JH, Gadia M, Lemerman R, Caswell K, Skyler JS, et al. Use of plaster casts in the management of diabetic neuropathic foot ulcers. Diabetes Care 1986; 9: 149–152.
19. Fletcher A, Cullum N, Sheldon TA. A systematic review of compression treatment for venous leg ulcers. BMJ 1997; 316: 576–580.
20. Winter GD. Formation of a scab and the rate of epithelialisation of superficial wounds in the skin of the young domestic pig. Nature 1962; 193: 293–294.
21. Rees RS, Robson MC, Smiell JM, Perry BH Pressure Ulcer Study Group. Becaplermin gel in the treatment of pressure ulcers. Wound Repair Regen 1997; 7: 141–147.
22. Gough A, Clapperton M, Rolando N, Foster AVM, Philpott-Howard J, Edmonds ME. Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. Lancet 1997; 350: 833–859.
23. Robson MC, Phillips LG, Lawrence WT, Bishop JB, Youngerman JS, Hayward PG, et al. The safety and effect of topically applied recombinant basic fibroblast growth factor on healing of chronic pressure sores. Ann Surg 1992; 216: 401–408.
24. Falanga V, Eaglstein WH, Bucalo B, Katz MH, Harris B, Carson P. Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers. J Dermatol Surg Oncol 1992; 18: 604–606.
25. Eldad A, Burt A, Clarke JA. Cultured epithelium as a skin substitute. Burns 1987; 13(3): 173–180.
26. Hansbrough JF. Dermagraft-TC for partial thickness burns: a clinical evaluation. J Burn Care Rehabil 1997; 18s: 25–28.
27. Gentzkow GD, Iwasaki SD, Hershon KS, Mengel M, Prendergast JJ, Ricotta JJ, et al. Use of Dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 1996; 19: 350–354.
28. Veves A, Falanga V, Armstrong DG, Sabolinski ML. Graftskin, a human skin equivalent is effective in the management of non infected neuropathic diabetic foot ulcers. Diabetes Care 2001; 24: 290–295.
29. Falanga V, Margolis D, Alvarez O, Auletta M, Maggiacomo F, Altman M, et al the Human Skin Equivalent Investigators Group. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Arch Dermatol 1998; 134: 293–300.
30. Taub PJ, Silver L, Weinberg H. Plastic surgical perspectives on vascular endothelial growth factor as gene therapy for angiogenesis. Plast Reconstruct Surg 2000; 105: 1034–1042.